| 3.12 0.09 (2.97%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.78 |
1-year : | 4.14 |
| Resists | First : | 3.24 |
Second : | 3.54 |
| Pivot price | 3.17 |
|||
| Supports | First : | 2.75 |
Second : | 2.28 |
| MAs | MA(5) : | 3.09 |
MA(20) : | 3.16 |
| MA(100) : | 3.23 |
MA(250) : | 5.01 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.4  |
D(3) : | 38.6 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 13.6 | Low : | 2.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed above bottom band by 39.3%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.19 | 3.19 - 3.2 |
| Low: | 2.94 - 2.96 | 2.96 - 2.98 |
| Close: | 3.09 - 3.13 | 3.13 - 3.15 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Thu, 19 Sep 2024
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction - StockTitan
Mon, 16 Sep 2024
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 - StockTitan
Mon, 09 Sep 2024
Evaxion reports high response rate in melanoma trial - Investing.com
Mon, 09 Sep 2024
Evaxion Biotech reports 69% ORR in Phase 2 trial on EVX-01 - TipRanks
Mon, 09 Sep 2024
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 - StockTitan
Mon, 09 Sep 2024
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 3.514e+007 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.88e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 974.6 % |
| Return on Equity (ttm) | -74.7 % |
| Qtrly Rev. Growth | 278000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.92 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.53 |
| Dividend | 0 |
| Forward Dividend | 34120 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|